CALT News and Press, Calliditas Therapeutics AB From 05/21/24

CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action PR Newswire STOCKHOLM , May 16, 2024 /PRNewswire/...

Invitation to the presentation of Calliditas´s interim report January - March 2024 PR Newswire STOCKHOLM , May 16, 2024 /PRNewswire/ -- Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on ...

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm PR Newswire STOCKHOLM , May 15, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM : CALTX) ("Calliditas"), today announced upcoming data presenta...

2024-05-14 08:01:12 ET More on Calliditas Therapeutics Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript Calliditas releases phase 2 results on head and neck cancer asset setanaxib Seeking Alpha’s Quant Rating on Calliditas Therapeutics...

Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China PR Newswire STOCKHOLM , May 14, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner ...

2024-05-06 11:52:08 ET More on Calliditas Therapeutics Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Calliditas Therapeutics Historical earnings data for Calliditas Therapeutics Financial info...

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM , May 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Callid...

2024-04-30 00:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Calliditas Therapeutics' 2023 Annual Report Published PR Newswire STOCKHOLM , April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM : CALTX ) ("Calliditas") today announces that the Annual Report for 2023 now is...